High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)

Journal of Clinical Pathology

Volumn 59, Issue 3, 2006, Pages 255-259

  Sonnweber, B ^b   Dlaska, M ^b   Skvortsov, S ^b   Dirnhofer, S ^c,d   Schmid, T ^a   Hilbe, W ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR V III; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN P53; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FROZEN SECTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SEX;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33644760776     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.027615     Document Type: Article

References (47)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
2. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin Oncol 2002;20:2881-94.
3. Bunn PA Jr, Shepherd FA, Sandler A, et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003;41:175-86.
4. Kris MG, Azzoli CG, Miller VA. Epidermal growth factor receptor blockade: targeted therapy for non-small-cell lung cancer. In: ASCO Educational Book. Alexandria, USA: ASCO, 2002:693-699.
5. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.
6. Hong WK, Ullrich A. The role of EGFR in solid tumours and implications for therapy. Oncol Biother 2000;1:1-35.
7. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004;10:136-43.
8. Arteaga CL. Epidermal growth factor receptors and erbB-2 in human lung cancer. In: Pass HI, eds. Lung cancer: principles and practice. MA: Lippincott-Raven, 1996:99-106.
9. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:9-15.
10. Konematsu T, Yano S, Uehara H, et al. Phosphorylation, But not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncology Res 2003;13:289-98.
11. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 1995;55:5536-9.
12. Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003;94:50-6.
13. Lorimer IAJ. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002;2:91-102.
14. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993;53:3217-20.
15. Fernandes H, Cohen S, Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem 2001;276:5375-83.
16. Chu CT, Everiss KD, Wikstrand CJ, et al. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997;324:855-61.
17. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273:200-6.
18. Moscatello DK, Montgomery RB, Sundareshan P, et al. Transformational and altered signal transduction by a natural occuring mutant EGF receptor. Oncogene 1996;13:85-96.
19. Feldkamp MM, Lala P, Lau N, et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999;45:144253.
20. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-68.
21. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. J Clin Pathol 2003;56:736-41.
22. Voldborg BR, Damstrup L, Spang-Thomsen M, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197-206.
23. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994;9:2313-20.
24. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumour radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-8.
25. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
26. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
27. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
28. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotherapy [abstract]. Proc Annu Meet Am Assoc Cancer Res 2004;22:P7022.
29. Shin DM, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of ci-1033, a novel pan-erbb tyrosine kinase inhibitor in patients with solid tumours [abstract]. Proc Annu Meet Am Assoc Cancer Res 2001;20:P324.
30. Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001;61:5349-54.
31. Hilbe W, Dlaska M, Dirnhofer S, et al. Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimens. Int J Oncol 2003;23:893-9.
32. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995;31:178-83.
33. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996;32:2070-4.
34. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
35. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996;2:1787-93.
36. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumour progression. Clin Cancer Res 1997;3:515-22.
37. Pfeiffer P, Nexø E, Bentzen SM, et al. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparison with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 1998;78:96-9.
38. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5.
39. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumour specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55:3140-8.
40. Pedersen MW, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
41. Srinivasan R, Leverton KE, Sheldon H, et al. Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. Cell Signal 2001;13:321-30.
42. Hubbard SR, Wei L, Ellis L, et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994;372:746-54.
43. Biscardi JS, Maa MC, Tice DA, et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
44. Prigent SA, Nagane M, Lin H, et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996;271:25639-45.
45. Huang H-JS, Nagane M, Klingbeil CK, et al. The enhanced tumourigenic activity of a mutant epidermal growth factor receptor common in human cancer is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-35.
46. Harpole DH Jr, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
47. Herbst RS, Opresko LK, Walsh BJ, et al. Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J Biol Chem 1994;269:12865-73.